QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)
Close on Nov 18, 2026Market cap $656.27MP/E –Yield –
QuidelOrtho operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
QuidelOrtho's operating income for the twelve months ending Sep 27, 2026 was -$127.40M. For fiscal 2025 it was -$919.20M. The highest annual figure on record is $1.06B in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | -$919.20M | – |
| FY2024 | Dec 29, 2024 | -$1.96B | -1509.7% |
| FY2023 | Dec 31, 2023 | $139.10M | -83.5% |
| FY2022 | Jan 1, 2023 | $843.70M | -6.9% |
| FY2021 | Jan 2, 2022 | $906.00M | -14.6% |
| FY2020 | Jan 3, 2021 | $1.06B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | -$7.50M | – |
| Q2 FY2026 | Jun 28, 2026 | -$21.80M | – |
| Q1 FY2026 | Mar 29, 2026 | -$31.80M | -197.5% |
| Q4 FY2025 | Dec 28, 2025 | -$66.30M | – |
| Q3 FY2025 | Sep 28, 2025 | -$704.80M | -4798.7% |
| Q2 FY2025 | Jun 29, 2025 | -$180.70M | – |
| Q1 FY2025 | Mar 30, 2025 | $32.60M | – |
| Q4 FY2024 | Dec 29, 2024 | -$100.40M | -350.4% |
| Q3 FY2024 | Sep 29, 2024 | $15.00M | -43.0% |
| Q2 FY2024 | Jun 30, 2024 | -$117.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.76B | -1865.1% |
| Q4 FY2023 | Dec 31, 2023 | $40.10M | -53.6% |
| Q3 FY2023 | Oct 1, 2023 | $26.30M | -53.7% |
| Q2 FY2023 | Jul 2, 2023 | -$26.90M | -133.8% |
| Q1 FY2023 | Apr 2, 2023 | $99.60M | -84.0% |
| Q4 FY2022 | Jan 1, 2023 | $86.50M | -77.0% |
| Q3 FY2022 | Oct 2, 2022 | $56.80M | -79.8% |
| Q2 FY2022 | Jul 3, 2022 | $79.70M | +242.1% |
| Q1 FY2022 | Apr 3, 2022 | $620.70M | – |
| Q4 FY2021 | Jan 2, 2022 | $376.70M | – |
| Q3 FY2021 | Oct 3, 2021 | $281.80M | – |
| Q2 FY2021 | Jul 4, 2021 | $23.30M | – |
See a number that looks wrong?